CNS Drugs

, Volume 12, Issue 5, pp 369–381 | Cite as

Prevention and Treatment of Motion Sickness in Children

  • Carlos R. Gordon
  • Avi Shupak
Disease Management


Motion sickness is a normal and transient response to unfamiliar or unnatural motion stimuli. The most common form of motion sickness in children appears to be car or bus sickness (travel sickness), and that produced by amusement park rides. An explanation for the causation and pathogenesis of motion sickness is provided by the neural mismatch and sensory rearrangement theory. This hypothesises that symptoms and signs of motion sickness are the result of a CNS response to unnatural motion stimuli transmitted to the vestibular nuclei, the archicerebellum, and to other brainstem, autonomic and hypothalamic areas.

There are very few studies of motion sickness in children, and no controlled studies of its pharmacological treatment in the paediatric population. It is generally agreed that infants are highly resistant to motion sickness and do not require pharmacological treatment. Susceptibility then increases with age, peaking at around 10 to 12 years. If the nonpharmacological measures designed to reduce neural sensory mismatch are insufficient to ameliorate motion sickness, the use of pharmacological treatment is advised. All agents that have some central or peripheral vestibular suppressant effect, acting on relevant areas before motion impulses reach the vomiting centre, will be effective in the prevention or active treatment of motion sickness. As motion sickness is a form of vertigo, it is not surprising that all anti-motion sickness drugs are considered antivertigo drugs. Antihistamines are the only drugs recommended for children. Cinnarizine, cyclizine, dimenhydrinate and promethazine, taken before departure, are all effective in the prevention of motion sickness. Rectal or parenteral administration are recommended for active treatment when signs of motion sickness have already appeared.

The development of new anti-motion sickness and antivertigo agents, based on recent neurochemical data, seems to be a promising field of investigation. Any such investigation should include controlled studies in children.


Migraine Motion Sickness Cinnarizine Dimenhydrinate Betahistine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Reason JT, Brand JJ. Motion sickness. London: Academic Press, 1975Google Scholar
  2. 2.
    Tyler DB, Bard P. Motion sickness. Physiol Rev 1949; 29: 311–69PubMedGoogle Scholar
  3. 3.
    Money KE. Motion sickness. Physiol Rev 1970; 50: 1–39PubMedGoogle Scholar
  4. 4.
    Graybiel A, Knepton J. Sopite syndrome: a sometimes sole manifestation of motion sickness. Aviat Space Environ Med 1976; 47: 873–82PubMedGoogle Scholar
  5. 5.
    Rolnick A, Gordon CR. The effects of motion induced sickness on military performance. In: Gal R, Mangelsdorff AD, editors. Handbook of military psychology. Chichester: John Wiley & Sons, Ltd, 1991: 279–93Google Scholar
  6. 6.
    Gordon CR, Spitzer O, Doweck I, et al. Clinical features of mal de débarquement: adaptation and habituation to sea conditions. J Vestib Res 1995; 5: 363–9PubMedCrossRefGoogle Scholar
  7. 7.
    Kennedy RS, Fowlkes JE, Lilienthal MG. Postural and performance changes following exposures to flight simulators. Aviat Space Environ Med 1993; 64: 912–20PubMedGoogle Scholar
  8. 8.
    Takahashi M, Toriyabe I, Takei Y, et al. Study on experimental motion sickness in children. Acta Otolaryngol (Stockh) 1994; 114: 231–7CrossRefGoogle Scholar
  9. 9.
    Takahashi M, Ogata M, Miura M. Teleology of motion sickness. Acta Otolaryngol (Stockh) 1995; 115: 130–3CrossRefGoogle Scholar
  10. 10.
    Takahashi M, Ogata M, Miura M. The significance of motion sickness in the vestibular system. J Vestib Res 1997; 7: 179–87PubMedCrossRefGoogle Scholar
  11. 11.
    Lawther A, Griffin MJ. A survey of the occurrence of motion sickness amongst passengers at sea. Aviat Space Environ Med 1988; 59: 399–406PubMedGoogle Scholar
  12. 12.
    Banta GR, Ridley WC, McHugh J, et al. Aerobic fitness and susceptibility to motion sickness. Aviat Space Environ Med 1987; 58: 105–8PubMedGoogle Scholar
  13. 13.
    Whinnery JE, Parnell MJ. The effects of long-term aerobic conditioning on +Gz tolerance. Aviat Space Environ Med 1987; 58: 199–204PubMedGoogle Scholar
  14. 14.
    Jennings RT, Davis JR, Santy PA. Comparison of aerobic fitness and space motion sickness during the shuttle program. Aviat Space Environ Med 1988; 59: 448–51PubMedGoogle Scholar
  15. 15.
    Sharma K. Prevalence and correlates of susceptibility to motion sickness. Acta Genet Med Gemellol 1997; 46: 105–21PubMedGoogle Scholar
  16. 16.
    Reason JT. Motion sickness adaptation: a neural mismatch model. J R Soc Med 1978; 71: 819–29PubMedGoogle Scholar
  17. 17.
    Brandt T, Daroff RB. The multisensory physiological and pathological vertigo syndromes. Ann Neurol 1980; 7: 195–203PubMedCrossRefGoogle Scholar
  18. 18.
    Baloh RW, Honrubia V. Clinical neurophysiology of the vestibular system. 2nd ed. Philadelphia (PA): FA Davis Company, 1990Google Scholar
  19. 19.
    Brandt T. Vertigo: its multisensory syndromes. London: Springer-Verlag, 1991CrossRefGoogle Scholar
  20. 20.
    Rascol O, Hain TC, Brefel C, et al. Antivertigo medications and drug-induced vertigo. A pharmacological review. Drugs 1995; 50: 777–91Google Scholar
  21. 21.
    Barabas G, Matthews WS, Ferrari M. Childhood migraine and motion sickness. Pediatrics 1983; 72: 188–90PubMedGoogle Scholar
  22. 22.
    Kuritzky A, Ziegler DK, Hassanein R. Vertigo, motion sickness and migraine. Headache 1981; 21: 227–31PubMedCrossRefGoogle Scholar
  23. 23.
    Baloh RW Neurotology of migraine. Headache 1997; 37: 615–21PubMedCrossRefGoogle Scholar
  24. 24.
    Baloh RW. Advances in neuro-otology. Curr Opin Neurol 1998; 11: 1–3PubMedCrossRefGoogle Scholar
  25. 25.
    Koehler B. Benign paroxysmal vertigo of childhood: amigraine equivalent. Eur J Pediatr 1980; 134: 149–51PubMedCrossRefGoogle Scholar
  26. 26.
    Abu-Arafeh I, Russell G. Paroxysmal vertigo as a migraine equivalent in children: a population-based study. Cephalalgia 1995; 15: 22–5PubMedCrossRefGoogle Scholar
  27. 27.
    Aragones JM, Fortes-Rego J, Fuste J, et al. Migraine: an alternative in the diagnosis of unclassified vertigo. Headache 1993; 33: 125–8PubMedCrossRefGoogle Scholar
  28. 28.
    Cutrer FM, Baloh RW. Migraine-associated dizziness. Headache 1992; 32: 300–4PubMedCrossRefGoogle Scholar
  29. 29.
    Cass SP, Furman JM, Ankerstjerne JKP, et al. Migraine-related vestibulopathy. Ann Otol Rhinol Laryngol 1997; 106: 182–9PubMedGoogle Scholar
  30. 30.
    Wood CD, Graybiel A. A theory of motion sickness based on pharmacological reactions. Clin Pharmacol Ther 1970; 11: 621–9PubMedGoogle Scholar
  31. 31.
    Takeda N, Morita M, Hasegawa S, et al. Neurochemical mechanisms of motion sickness. Am J Otolaryngol 1989; 10: 351–9PubMedCrossRefGoogle Scholar
  32. 32.
    Takeda N, Morita M, Hasegawa S, et al. Neuropharmacology of motion sickness and emesis. A review. Acta Otolaryngol (Stockh) 1993; Suppl. 501: 10–5CrossRefGoogle Scholar
  33. 33.
    Lucot JB. Pharmacology of motion sickness. J Vestib Res 1998; 8: 61–6PubMedCrossRefGoogle Scholar
  34. 34.
    Wang SC, Chinn HI. Experimental motion sickness in dogs; functional importance of chemoceptive emetic trigger zone. Am J Physiol 1954; 178: 111–6PubMedGoogle Scholar
  35. 35.
    Borison HL, Borison R. Motion sickness reflex arc bypasses the area postrema in cats. Exp Neurol 1986; 92: 723–37PubMedCrossRefGoogle Scholar
  36. 36.
    Brizzee KR, Ordy JM, Mehler WR. Effect of ablation of area postrema on frequency and latency of motion sickness-induced emesis in the squirrel monkey. Physiol Behav 1980; 24: 849–53PubMedCrossRefGoogle Scholar
  37. 37.
    Mitchelson F. Pharmacological agents affecting emesis. A review (part I). Drugs 1992; 43: 295–315PubMedGoogle Scholar
  38. 38.
    Mitchelson F. Pharmacological agents affecting emesis. A review (part II). Drugs 1992; 43: 443–63PubMedGoogle Scholar
  39. 39.
    Cowings PS, Suter S, Toscano WB, et al. General autonomic components of motion sickness. Psychophysiology 1986; 23: 542–51PubMedCrossRefGoogle Scholar
  40. 40.
    Gordon CR, Ben-Aryeh H, Szargel R, et al. Salivary changes associated with seasickness. J Auton Nerv Syst 1989; 26: 37–42PubMedCrossRefGoogle Scholar
  41. 41.
    Doweck I, Gordon CR, Shlitner A, et al. Alterations in R-R variability associated with experimental motion sickness. J Auton Nerv Syst 1997; 67: 31–7PubMedCrossRefGoogle Scholar
  42. 42.
    Kohl RL. Endocrine correlates of susceptibility to motion sickness. Aviat Space Environ Med 1985; 56: 1158–65PubMedGoogle Scholar
  43. 43.
    Matsuoka I, Ito J, Takahashi H, et al. Experimental vestibular pharmacology: a minireview with special reference to neuro-active substances and antivertigo drugs. Acta Otolaryngol (Stockh) 1985; Suppl. 419: 62–70Google Scholar
  44. 44.
    de Waele C, Muhlethaler M, Vidal PP. Neurochemistry of the central vestibular pathways. Brain Res Rev 1995; 20: 24–46PubMedCrossRefGoogle Scholar
  45. 45.
    Golding JF, Stott JRR. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) n motion sickness, skin conductance and heart rate. Br J Clin Pharmacol 1997; 43: 633–7PubMedCrossRefGoogle Scholar
  46. 46.
    Wood CD. Pharmacological countermeasures against motion sickness. In: Crampton GH, editor. Motion and space sickness. Boca Raton (FL): CRC Press, Inc., 1990: 343–51Google Scholar
  47. 47.
    Dobie TG, May JG. Cognitive-behavioral management of motion sickness. Aviat Space Environ Med 1994; 65(10 Suppl.): C1–20PubMedGoogle Scholar
  48. 48.
    Wood CD, Manno JE, Manno BR, et al. The effect of antimotion sickness drugs on habituation to motion. Aviat Space Environ Med 1986; 57: 539–42PubMedGoogle Scholar
  49. 49.
    Homick JL, Kohl RL, Reschke MF, et al. Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy. Aviat Space Environ Med 1983; 54: 994–1000PubMedGoogle Scholar
  50. 50.
    Attias J, Gordon C, Ribak J, et al. Efficacy of transdermal scopolamine against seasickness: a 3-day study at sea. Aviat Space Environ Med 1987; 58: 60–2PubMedGoogle Scholar
  51. 51.
    Gordon C, Binah O, Attias J, et al. Transdermal scopolamine: human performance and side effects. Aviat Space Environ Med 1986; 57: 236–40PubMedGoogle Scholar
  52. 52.
    Parrott AC. Transdermal scopolamine: a review of its effects upon motion sickness, psychological performance, and physiological functioning. Aviat Space Environ Med 1989; 60: 1–9PubMedGoogle Scholar
  53. 53.
    Sennhauser FH, Schwarz HP. Toxic psychosis from transdermal scopolamine in a child [letter]. Lancet 1986; 2(8514): 1033PubMedCrossRefGoogle Scholar
  54. 54.
    Klein BL, Ashenburg CA, Reed MD. Transdermal scopolamine intoxication in a child. Pediatr Emerg Care 1985; 1: 208–9PubMedCrossRefGoogle Scholar
  55. 55.
    Johnson SF, Moore RJ. Transderm pupil and confusion in a 10 year old [letter]. Ann Neurol 1983; 13: 583PubMedCrossRefGoogle Scholar
  56. 56.
    Doyle E, Byers G, McNicol LR, et al. Prevention of postoperative nausea and vomiting with transdermal hyoscine in children using patient-controlled analgesia. Br J Anaesth 1994; 72: 72–6PubMedCrossRefGoogle Scholar
  57. 57.
    Ayub N, Donaldson D, Bedford D, et al. Lessons to be learned: a case study approach. Hyperactivity and confusion in the presentation of hyoscine overdose. J R Soc Health 1997; 117: 242–4Google Scholar
  58. 58.
    Gordon CR, Shupak A, Doweck I, et al. Allergic contact dermatitis caused by transdermal hyoscine. Br Med J 1989; 298: 1220–1CrossRefGoogle Scholar
  59. 59.
    Gordon CR, Mankuta D, Shupak A, et al. Recurrent classic migraine attacks following transdermal scopolamine intoxication. Headache 1991; 31: 172–4PubMedCrossRefGoogle Scholar
  60. 60.
    Luetje CM, Wooten J. Clinical manifestations of transdermal scopolamine addiction. Ear Nose Throat J 1996; 75: 210–4PubMedGoogle Scholar
  61. 61.
    Reynolds JEF, editor. Martindale. The extra pharmacopoeia. 31st ed. London: Royal Pharmaceutical Society, 1996Google Scholar
  62. 62.
    Rowe C, Verjee Z, Koren G. Adolescent dimenhydrinate abuse: resurgence of an old problem. J Adolesc Health 1997; 21: 47–9PubMedCrossRefGoogle Scholar
  63. 63.
    Craig DF, Mellor CS. Dimenhydrinate dependence and withdrawal. Can Med Assoc J 1990; 142: 970–3Google Scholar
  64. 64.
    Bassett KE, Schunk JE, Crouch BL Cyclizine abuse by teenagers in Utah. Am J Emerg Med 1996; 14: 472–4PubMedCrossRefGoogle Scholar
  65. 65.
    Towse G. Cinnarizine — a labyrinthine sedative. J Laryngol Otol 1980; 94: 1009–15PubMedCrossRefGoogle Scholar
  66. 66.
    Philipszoon AJ. Influence of cinnarizine on the labyrinth and n vertigo. Clin Pharmacol Ther 1962; 3: 184–90PubMedGoogle Scholar
  67. 67.
    Hargreaves J. A double-blind placebo controlled study of cinnarizine in the prophylaxis of seasickness. Practitioner 1980; 224: 547–50PubMedGoogle Scholar
  68. 68.
    Hargreaves J. The prophylaxis of seasickness. A comparison of cinnarizine with hyoscine. Practitioner 1982; 226(1363): 160Google Scholar
  69. 69.
    Shupak A, Doweck I, Gordon CR, et al. Cinnarizine in the prophylaxis of seasickness: laboratory vestibular evaluation and sea study. Clin Pharmacol Ther 1994; 55: 670–80PubMedCrossRefGoogle Scholar
  70. 70.
    Doweck I, Gordon CR, Spitzer O, et al. Effect of cinnarizine in the prevention of seasickness. Aviat Space Environ Med 1994; 65: 606–9PubMedGoogle Scholar
  71. 71.
    Macnair AL. Cinnarizine in the prophylaxis of car sickness in children. Curr Med Res Opin 1983; 8: 451–5PubMedCrossRefGoogle Scholar
  72. 72.
    Holmes B, Brogden RN, Heel RC, et al. Flunarizine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 1984; 27: 6–44Google Scholar
  73. 73.
    Lee JA, Watson LA, Boothby G. Calcium antagonists in the prevention of motion sickness. Aviat Space Environ Med 1986; 57: 45–8PubMedGoogle Scholar
  74. 74.
    Wang J-J, Dutia MB. Effects of histamine and betahistine on rat medial vestibular nucleus neurones: possible mechanism of action of anti-histaminergic drugs in vertigo and motion sickness. xp Brain Res 1995; 105: 18–24Google Scholar
  75. 75.
    Schmidt JT, Huizing EH. The clinical drug trial in Meniere’s disease with emphasis on the effect of betahistine SR. Acta Otolaryngol (Stockh) 1992; Suppl. 497: 1–189Google Scholar
  76. 76.
    Gonen A, Doweck I, Spitzer O, et al. Betahistine in the prevention of seasickness and its effects on performance [abstract]. Aviat Space Environ Med 1995; 66: 467Google Scholar
  77. 77.
    Noble RL. The effect of barbiturates and other substances on motion sickness in dogs. Can J Res 1948; 26 (Sect. E): 283–94CrossRefGoogle Scholar
  78. 78.
    McClure JA, Lycett P, Baskerville JC. Diazepam as an anti-motion sickness drug. J Otolaryngol 1982; 11: 253–9PubMedGoogle Scholar
  79. 79.
    Chelen W, Kabrisky M, Hatsell C, et al. Use of phenytoin in the prevention of motion sickness. Aviat Space Environ Med 1990; 61: 1022–5PubMedGoogle Scholar
  80. 80.
    Knox GW, Woodard D, Chelen W, et al. Phenytoin for motion sickness: clinical evaluation. Laryngoscope 1994; 104: 935–9PubMedCrossRefGoogle Scholar
  81. 81.
    Grontved A, Brask T, Kambskard J, et al. Ginger root against seasickness. A controlled trial on the open sea. Acta Otolaryngol (Stockh) 1988; 105: 45–9Google Scholar
  82. 82.
    Stewart JJ, Wood MJ, Wood CD, et al. Effects of ginger on motion sickness susceptibility and gastric function. Pharmacology 1991; 42: 111–20PubMedCrossRefGoogle Scholar
  83. 83.
    Holtmann S, Clarke AH, Scherer H, et al. The anti-motion sickness mechanism of ginger. A comparative study with placebo and dimenhydrinate. Acta Otolaryngol (Stockh) 1989; 108: 168–74CrossRefGoogle Scholar
  84. 84.
    Lucot JB, Crampton GH. Buspirone blocks motion sickness and xylazine-induced emesis in the cat. Aviat Space Environ Med 1987; 58: 989–91PubMedGoogle Scholar
  85. 85.
    Okada F, Saito H, Matsuki N. Prophylactic effect of serotonin uptake inhibitors against motion sickness in Suncus murinus. Eur J Pharmacol 1996; 309: 33–5PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  1. 1.Department of Neurology, Meir General Hospital, Kfar Saba and Sackler School of MedicineTel Aviv UniversityTel AvivIsrael
  2. 2.Motion Sickness and Human Performance LaboratoryIsrael Naval Medical Institute, IDF Medical CorpsHaifaIsrael

Personalised recommendations